Thromb Haemost 1973; 30(02): 403-413
DOI: 10.1055/s-0038-1649090
Original Article
Schattauer GmbH

Preferential Degradation of Soluble Fibrin Monomers in Streptokinase-activated Plasma

Y. P Konttinen
1   Medical and Laboratory Departments of Maria Hospital, Helsinki, Finland
,
M.L.T Lalla
1   Medical and Laboratory Departments of Maria Hospital, Helsinki, Finland
,
O Turunen
1   Medical and Laboratory Departments of Maria Hospital, Helsinki, Finland
› Author Affiliations
Further Information

Publication History

Received for publication 04 April 1973

Accepted for publication 18 June 1973

Publication Date:
30 June 2018 (online)

Summary

Degradation of 125I-labelled fibrin monomers and 125I-fibrinogen in streptokinase-activated plasma was investigated. Release of the label proceeded at a much higher rate from soluble fibrin monomer complexes than from fibrinogen until ca. 70% of the label was recovered in the serum. It is concluded that the fibrinolytic system has an essentially higher affinity to monomers than to fibrinogen, but that the specificity of the monomers as substrate may be limited to the early steps of degradation. It is suggested that the preferential splitting of fibrin monomer complexes may be important in the body’s defence against pathological fibrin formations derived from paracoagulable fibrin.

 
  • References

  • 1 Derechin M. 1955; Caractères généraux de la paracoagulation fibrinolytique. Revue d’Hématologie 10: 35.
  • 2 Derechin M, and Szuchet S. 1956; Fibrinolytic paracoagulation with different substances. Acta Physiologica Latinoamericana 6: 170.
  • 3 Derechin M, and Szuchet S. 1960; Gelation phenomena in degraded fibrinogen and fibrin. Archives of Biochemistry and Biophysics 87: 100.
  • 4 Fearnley G. R, and Chakeabarti R. 1966; Fibrinolytic treatment of rheumatoid arthritis with phenphormin plus ethyloestranol. Lancet 2: 757.
  • 5 Fletcher A. P, Alkjaersig N, Fisher S, and Sherry S. 1966; The proteolysis of fibrinogen by plasmin: The identification of thrombin-clottable fibrinogen-derivatives which polymerize abnormally. Journal of Laboratory and Clinical Medicine 68: 780.
  • 6 Furlan M, and Beck E. A. 1972; Plasmic degradation of human fibrinogen. I. Structural characterization of degradation products. Biochimica et Biophysica Acta 263: 631.
  • 7 Godal H. C, and Abildgaard T.J. 1966; Gelation of soluble fibrin in plasma by ethanol. Scandinavian Journal of Haematology 3: 342.
  • 8 Hawiger J, Collins R. D, and Horn R. G. 1969; Precipitation of soluble fibrin monomer complexes by lysosomal protein fraction of polymorphonuclear leukocytes. Proceedings of the Society for Experimental Biology and Medicine 131: 349.
  • 9 Hoq M. C, and Das P. C. 1971; Preparation of human cells for the assay of serum fibrinogen degradation products using haemagglutination inhibition. Scandinavian Journal of Haematology, Suppl 13: 101.
  • 10 Konttinen Y. P. 1965 Activation of the Fibrinolytic System in Human Blood by Streptokinase and Changes in this System and in the Euglobulin Clot Lysis Time in Relation to Age and Sex. Scandinavian Journal of Clinical and Laboratory Investigation. Suppl. 82.
  • 11 Konttinen Y. P. 1973 Degradation of paracoagulable fibrin by fibrinolysin. To be published.
  • 12 Kopeć M, Kowalski E, and Stachurska J. 1960; Studies on paracoagulation. Role of antithrombin VI. Thrombosis et Diathesis Haemorrhagica 5: 285.
  • 13 Kopeć M, Wegrzynowicz Z, and Latallo Z. S. 1970; Precipitation of soluble fibrin monomer complexes SFMC by cellular basic proteins, and the antagonistic effect of sulfonated mucopolysaccharides. Proceedings of the Society for Experimental Biology and Medicine 135: 675.
  • 14 Lee L. 1962; Reticuloendothelial clearance of circulating fibrin in the pathogenesis of the generalized Shwartzman reaction. Journal of Experimental Medicine 115: 1065.
  • 15 Lipiński B, Hawiger J, and Jeljaszewicz J. 1967; a Staphylococcal clumping with soluble fibrin monomer complexes. Journal of Experimental Medicine 126: 979.
  • 16 Lipiński B, Wegrzynowicz Z, Budzynski A. Z, Kopeć M, Latallo Z. S, and Kowalski E. 1967; b Soluble unclottable complexes formed in the presence of fibrinogen degradation products (FDP) during the fibrinogen-fibrin conversion and their potential significance in pathology. Thrombosis et Diathesis Haemorrhagica 17: 65.
  • 17 Lipiński B, and Worowski K. 1968; Detection of soluble fibrin monomer complexes in blood by means of protamine sulphate test. Thrombosis et Diathesis Haemorrhagica 20: 44.
  • 18 Lipiński B, Worowski K, Jeljaszewicz J, Niewiarowski S, and Rejniak L. 1968; Participation of soluble fibrin monomer complexes and platelet factor 4 in the generalized Shwartzman reaction. Thrombosis et Diathesis Haemorrhagica 20: 285.
  • 19 Marder V. J, Shulman N. R, and Carroll W. R. 1969; High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization. Journal of Biological Chemistry 244: 2111.
  • 20 Meeskey C, Lalezari P, and Johnson A. J. 1969; A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proceedings of the Society for Experimental Biology and Medicine 131: 871.
  • 21 Mills D. 1972; A molecular model for the proteolysis of human fibrinogen by plasmin. Biochimica et Biophysica Acta 263: 619.
  • 22 Niewiarowski S, and Nandi M. 1971; Acrylamide gel electrophoresis of fibrinogen and fibrin degradation products. British Journal of Haematology 21: 71.
  • 23 Niewiarowski S, Poplawski A, Lipiński B, and Farbiszewski R. 1968; The release of platelet clotting factors during aggregation and viscous metamorphosis. Experimental Biology and Medicine 3: 121.
  • 24 Nussenzweig V, Seligmann M, and Grabar P. 1961; a Les produits de dégradation du fibrinogène humain par la plasmine. II. Étude immunologique : Mise en évidence d’anticorps anti-fibrinogène natif possédant des spécificités différentes. Annales de l’Institut Pasteur 100: 490.
  • 25 Nussenzweig V, Seligmann M, Pelmont T.J, and Grabar P. 1961; b Les produits de dégradation du fibrinogène humain par la plasmine. I. Séparation et propriétés physico- chimiques. Annales de l’Institut Pasteur 100: 377.
  • 26 Pizzo S. V, Schwartz M. L, Hill R. L, and McKee P. A. 1972; The effect of plasmin on the subunit structure of human fibrinogen. Journal of Biological Chemistry 247: 636.
  • 27 Regoeczi E. 1971; Iodine-labelled fibrinogen: A Review. British Journal of Haematology 20: 649.
  • 28 Shainoff J. R, and Page I. H. 1960; Cofibrins and fibrin-intermediates as indicators of thrombin activity in vivo. Circulation Research 8: 1013.
  • 29 Shainoff J. R, and Page I. H. 1962; Significance of oryoprofibrin in fibrinogen-fibrin conversion. Journal of Experimental Medicine 116: 687.
  • 30 Sherman L. A, Mosesson M. W, and Sherry S. 1969; Isolation and characterization of the clottable low molecular weight fibrinogen derived by limited plasmin hydrolysis of human fraction 1-4. Biochemistry 8: 515.
  • 31 Shimamoto T, Kobayashi M, and Numano F. 1972; Infiltration of γ-globulin, fibrinogen and ß-lipoprotein into blood vessel wall by atherogenic stress visualized by immunofluorescence. Proceedings of the Japan Academy 48: 336.
  • 32 Stewart G. J, and Niewiarowski S. 1971; Aggregation of fibrinogen and its degradation products by basic proteins. An electron microscope study. Thrombosis et Diathesis Haemorrhagica 25: 566.
  • 33 Still W. J, and Scott G. B. 1966; An electron microscopic study of the endothelial changes and the nature of “fibrinoid” produced in the generalized Shwartzman reaction. Experimental and Molecular Pathology 5: 118.
  • 34 Wegrzynowicz Z, Kopeć M, and Latallo Z. S. 1971; Formation of soluble fibrin complexes and some factors affecting their solubility. Scandinavian Journal of Haematology, Suppl 13: 49.